Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2020 07:21 ET | Source: AC Immune SA

AC Immune Announces Results of Annual General Meeting

LAUSANNE, Switzerland, June 26, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
May 15, 2020 07:00 ET | Source: AC Immune SA

AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference

LAUSANNE, Switzerland, May 15, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
May 04, 2020 07:00 ET | Source: AC Immune SA

AC Immune Reports Q1 2020 Financial Results and Provides Business Update

On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19Ongoing strong financial position with CHF 277.9 million in cash, ensuring the Company...
April 02, 2020 07:00 ET | Source: AC Immune SA

AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases

Seven presentations by AC Immune and its partners at AAT-AD/PD™ New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates A lead anti-alpha-synuclein therapeutic...
March 30, 2020 07:00 ET | Source: AC Immune SA

AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook

Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestonesReceived CHF 110 million in upfront and...
March 23, 2020 07:00 ET | Source: AC Immune SA

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

CHF 10 million milestone recognizes development progressUpdated financial terms add a new CHF 60 million milestone for Phase 2 initiationTotal potential deal value is now CHF 1.86 billion, up from CHF...
March 20, 2020 07:18 ET | Source: AC Immune SA

Internationally Renowned Neurologist Dr. Juan Fortea Joins AC Immune’s Clinical Advisory Board

LAUSANNE, Switzerland, March 20, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
March 05, 2020 07:00 ET | Source: AC Immune SA

AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting

LAUSANNE, Switzerland, March 05, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, announced today that four new data presentations will...
November 14, 2019 07:00 ET | Source: AC Immune SA

AC Immune to Present at Jefferies 2019 London Healthcare Conference

LAUSANNE, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative...
November 13, 2019 07:00 ET | Source: AC Immune SA

AC Immune Q3 2019 Financial Results and Business Update

CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE...